 Puma Biotechnology NASDAQ:PBYI had its price target decreased by SVB Leerink from 14.00 to 10.00 in a report published on Friday, BenzingaRatingsTable reports. SVB Leerink currently has a market perform rating on the biopharmaceutical companys stock. Several other research analysts have also issued reports on PBYI. Bank of America assumed coverage on Puma Biotechnology in ... 